Observational Study of Etrasimod Treatment in Adults with Moderate to Severe Ulcerative Colitis

What this Trial Is About

Researchers are evaluating the effects of etrasimod as a treatment for adults with moderate to severe ulcerative colitis who have not previously taken this medication. This observational study aims to understand how etrasimod impacts disease activity by comparing patients symptoms before and after starting treatment. The study includes patients who are prescribed etrasimod as part of their standard medical care. All participants will receive etrasimod according to regular medical practice without additional experimental treatments. Health questionnaires about ulcerative colitis symptoms will be completed by patients at various times throughout the study using their personal mobile phone, tablet, or computer. The study period lasts 52 weeks, followed by a 28-day safety follow-up after treatment. During the study, patients will attend doctor visits and undergo tests as part of routine care. Researchers will collect patient-reported symptom information through digital questionnaires to assess outcomes such as symptomatic remission and response at multiple time points up to one year. Safety and changes in symptoms like bowel urgency, abdominal pain, and fatigue will also be monitored. The total participation time is just over one year, including follow-up after treatment ends.

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis